Insights into ligand pharmacology using receptor-G-protein fusion proteins.
about
Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapesPalmitoylation regulates regulators of G-protein signaling (RGS) 16 function. I. Mutation of amino-terminal cysteine residues on RGS16 prevents its targeting to lipid rafts and palmitoylation of an internal cysteine residueMu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cellsDifferential capacities of the RGS1, RGS16 and RGS-GAIP regulators of G protein signaling to enhance alpha2A-adrenoreceptor agonist-stimulated GTPase activity of G(o1)alpha.beta-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations.A G protein-coupled receptor (GPCR) in red: live cell imaging of the kappa opioid receptor-tdTomato fusion protein (KOPR-tdT) in neuronal cells.G-protein-coupled receptors in drug discovery: nanosizing using cell-free technologies and molecular biology approaches.Smoothened is a fully competent activator of the heterotrimeric G protein G(i).Low affinity GPCRs for metabolic intermediates: challenges for pharmacologists.Heterodimerisation of G protein-coupled receptors: implications for drug design and ligand screening.Coordinated agonist regulation of receptor and G protein palmitoylation and functional rescue of palmitoylation-deficient mutants of the G protein G11alpha following fusion to the alpha1b-adrenoreceptor: palmitoylation of G11alpha is not required foThe human delta opioid receptor activates G(i1)alpha more efficiently than G(o1)alpha.Impact of fusion to Gα(i2) and co-expression with RGS proteins on pharmacological properties of human cannabinoid receptors CB₁R and CB₂R.Co-expression of mu and delta opioid receptors as receptor-G protein fusions enhances both mu and delta signalling via distinct mechanisms.Activation of an alpha2A-adrenoceptor-Galphao1 fusion protein dynamically regulates the palmitoylation status of the G protein but not of the receptor.Pharmacological analysis of a dopamine D(2Short):G(alphao) fusion protein expressed in Sf9 cells.Regulation of the avidity of ternary complexes containing the human 5-HT(1A) receptor by mutation of a receptor contact site on the interacting G protein alpha subunit.Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid receptor differently.The olfactory G protein G(alphaolf) possesses a lower GDP-affinity and deactivates more rapidly than G(salphashort): consequences for receptor-coupling and adenylyl cyclase activation.ER/K linked GPCR-G protein fusions systematically modulate second messenger response in cellsDistinct interactions of GTP, UTP, and CTP with G(s) proteins.The regulator of G protein signaling RGS4 selectively enhances alpha 2A-adreoreceptor stimulation of the GTPase activity of Go1alpha and Gi2alpha.Functional coupling with Galpha(q) and Galpha(i1) protein subunits promotes high-affinity agonist binding to the neurotensin receptor NTS-1 expressed in Escherichia coli.Promiscuous coupling at receptor-Galpha fusion proteins. The receptor of one covalent complex interacts with the alpha-subunit of another.Coupling efficacy and selectivity of the human mu-opioid receptor expressed as receptor-Galpha fusion proteins in Escherichia coli.Pharmacological characterization of putative beta1-beta2-adrenergic receptor heterodimers.Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins.
P2860
Q24633877-5828B267-DF79-4CF3-8CA7-A865CB7E3216Q28184264-300C3DF6-6574-4292-AFA1-1EFCD92CD28AQ28344890-3B62C4AF-C136-476D-8B18-9D233A51B0F3Q34088047-7B2608DE-65CC-40B7-BFE7-6A4E1CFC8093Q34233952-F337A11A-AAD0-466F-8304-4A9B99F1AF91Q34821230-00940865-0D64-4F31-8AC1-FC87962D265AQ36290216-779A00A2-5242-4D05-92C1-7DBD368B4BEFQ36642393-E2DCE6C0-E6AF-4A0B-BF7E-AD6AEDF84157Q38014830-9569517A-AFFB-40FD-BAD3-57DAE3BDFA31Q38028547-626EE136-78EC-40BD-9CD0-CEC08729D432Q38298775-EB2597AA-861C-4103-8717-7820C9F57258Q38525200-89D9D370-9B95-4550-A63D-52FE916B76F8Q39515353-77741C38-C5EE-4732-AE2B-188B205D7FD9Q40027304-97DE7261-5007-4466-BA82-448E825C919DQ40516412-7E8B03B5-7337-4241-9934-CAD71562151DQ40640011-99807D92-9DE0-4270-93DA-7FF1D56E1D88Q40703432-B682C438-32E1-4831-A3BF-6FBF8E8F2A22Q40724494-F718C816-D7BB-461F-9D10-CDB5822F35C4Q40791394-2F5419CB-8CE8-4B70-A750-A8201E5D4BAAQ41354226-0384326E-8347-4147-883E-87E94400FFB7Q42051125-E745A55D-1FB8-4DD8-BD12-6EBE6A47831AQ42487898-19F18EC5-54B0-4EAC-B291-0506A65BC196Q43564870-4629C0D0-E667-428A-BECC-9DA83410D1AEQ44323333-781C187D-C4BC-4691-AE58-104B8B1CC9FDQ44332712-4FC56249-DAB9-4683-A1EC-C898A6928E35Q44413518-BEDB7F46-D679-43AF-A6B2-61C71FCF9014Q44550521-9C4104E9-15E6-4A83-B0CB-8E5CD6337A83
P2860
Insights into ligand pharmacology using receptor-G-protein fusion proteins.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Insights into ligand pharmacology using receptor-G-protein fusion proteins.
@ast
Insights into ligand pharmacology using receptor-G-protein fusion proteins.
@en
type
label
Insights into ligand pharmacology using receptor-G-protein fusion proteins.
@ast
Insights into ligand pharmacology using receptor-G-protein fusion proteins.
@en
prefLabel
Insights into ligand pharmacology using receptor-G-protein fusion proteins.
@ast
Insights into ligand pharmacology using receptor-G-protein fusion proteins.
@en
P1476
Insights into ligand pharmacology using receptor-G-protein fusion proteins.
@en
P2093
Milligan G
P356
10.1016/S0165-6147(99)01404-2
P577
2000-01-01T00:00:00Z